Alvotech and Advanz Pharma Team Up to Commercialize AVT06/AVT29 (Biosimilar, Eylea) in Europe
Shots:
- Alvotech has signed an exclusive partnership agreement with Advanz Pharma to supply and commercialize AVT06 (2mg, Low dose) and AVT29 (8mg, High dose), biosimilars of Eylea
- As per the agreement, Alvotech will develop & supply the biosimilars and receive an upfront plus subsequent development & commercialization milestones. Advanz Pharma will handle registration & commercialization, with exclusive rights in EU (semi-exclusive in Germany & France)
- AVT06/AVT29 is a VEGF targeting recombinant fusion protein. The equivalence of AVT06 vs Eylea in patients with neovascular (wet) AMD was demonstrated in the study assessing its efficacy, safety and immunogenicity
Ref: Alvotech | Image: Alvotech
Related News:- Alvotech Reports Topline Results from the Study of AVT06 (Biosimilar, Eylea) for Eye Disorders
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
